Atossa Genetics Inc (NASDAQ: ATOS) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced that it would be hosting a conference all soon to discuss key clinical findings. Of course, this led to excitement among investors, sending the stock screaming for the top. Today, we’ll talk about the news, what we’re seeing from ATOS as a result, and what we’ll be watching for ahead.
ATOS Gains On Coming Data Release
As mentioned above, Atossa Genetics is having an incredibly strong start to the trading session in the pre-market hours this morning after announcing that it will be releasing data soon. In a press release issued early this morning, the company announced that it will be hosting a conference call tomorrow, February 1, 2018 at 4:20 PM EST. In the release, ATOS said that the call will be to discuss additional findings from a Phase 1 clinical trial of oral Endoxifen. Endoxifen is an active metabolite of the FDA-approved drug known as tamoxifen. Tamoxifen is currently being used as a treatment for breast cancer as well as a preventative measure in patients at high risk for developing breast cancer.
If you’d like to take part in the conference call, you can preregister here. If you decide to preregister, you will receive a dial in number upon registration, giving you the ability to call in without delay. However, if you are unable to preregister, the call can be accessed by calling (844) 824 – 2830 (United States) or 1 (412) 317-5140 (international). If you are in Canada, you can call in toll free at (855) 669-9657. Once you call, be sure to ask to be joined into the ATOS call.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!